ArticleTargeted oncology2023

Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.

Ning Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.